Literature DB >> 6867005

Long-term persistence of antibody following immunization with pneumococcal polysaccharide vaccine.

M A Mufson, H E Krause, G Schiffman.   

Abstract

Thirty-seven healthy volunteers who received a pneumococcal polysaccharide vaccine were tested 4, 5, or 6 years after immunization for circulating type-specific pneumococcal antibody by radioimmunoassay of their sera. Each volunteer was immunized with one of four different pneumococcal vaccines containing 50 micrograms of each of 6, 8, 9, or 13 capsular polysaccharides; a few volunteers received octavalent or tridecavalent pneumococcal vaccines combined with bivalent influenza virus vaccine in a single syringe. Four years after immunization, the mean antibody level was 90% of the level achieved 4 weeks after vaccination. Among volunteers tested 5 years after immunization (including three 6 years after vaccination), the mean antibody level was 76% of that 4 weeks after inoculation. These findings confirm the long-term persistence of vaccine-induced type-specific pneumococcal antibodies and suggest that the interval between repeated doses of pneumococcal vaccine should be at least 5 years.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6867005     DOI: 10.3181/00379727-173-41643

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN: 0037-9727


  13 in total

Review 1.  Pneumococcal and influenza vaccination: current situation and future prospects.

Authors:  F Horwood; J Macfarlane
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

Review 2.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

Review 3.  Immunizations in the elderly.

Authors:  D W Bentley
Journal:  Bull N Y Acad Med       Date:  1987 Jul-Aug

Review 4.  The use of vaccines in renal failure.

Authors:  D W Johnson; S J Fleming
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

5.  Purification and immunogenicity of genetically obtained pneumolysin toxoids and their conjugation to Streptococcus pneumoniae type 19F polysaccharide.

Authors:  J C Paton; R A Lock; C J Lee; J P Li; A M Berry; T J Mitchell; P W Andrew; D Hansman; G J Boulnois
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

6.  Poor antibody response after tetanus and pneumococcal vaccination in immunocompromised, HIV-infected patients.

Authors:  M Opravil; W Fierz; L Matter; J Blaser; R Lüthy
Journal:  Clin Exp Immunol       Date:  1991-05       Impact factor: 4.330

7.  Revaccination of adults with spinal cord injury using the 23-valent pneumococcal polysaccharide vaccine.

Authors:  Ken B Waites; Kay C Canupp; Yu-Ying Chen; Michael J DeVivo; Moon H Nahm
Journal:  J Spinal Cord Med       Date:  2008       Impact factor: 1.985

8.  Pneumococcal antibodies (IgG, IgM) in patients with chronic obstructive lung disease 3 years after pneumococcal vaccination.

Authors:  C Kraus; S Fischer; R Ansorg; U Hüttemann
Journal:  Med Microbiol Immunol       Date:  1985       Impact factor: 3.402

9.  Pneumococcal sepsis and meningitis in vaccinated subjects: a review of 55 reported cases.

Authors:  M H Zarrabi; F Rosner
Journal:  J Natl Med Assoc       Date:  1987-04       Impact factor: 1.798

10.  Immunogenicity in a mouse model of a conjugate vaccine made with a synthetic single repeating unit of type 14 pneumococcal polysaccharide coupled to CRM197.

Authors:  Fatme Mawas; Jutta Niggemann; Christopher Jones; Michael J Corbel; Johannis P Kamerling; Johannes F G Vliegenthart
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.